AR035534A1 - Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion - Google Patents
Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicionInfo
- Publication number
- AR035534A1 AR035534A1 ARP020100289A ARP020100289A AR035534A1 AR 035534 A1 AR035534 A1 AR 035534A1 AR P020100289 A ARP020100289 A AR P020100289A AR P020100289 A ARP020100289 A AR P020100289A AR 035534 A1 AR035534 A1 AR 035534A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- cell
- plant
- polyunsaturated fatty
- vegetable
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000009261 transgenic effect Effects 0.000 title abstract 2
- 235000013311 vegetables Nutrition 0.000 title 2
- 241000124008 Mammalia Species 0.000 title 1
- 239000004744 fabric Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract 7
- 238000004519 manufacturing process Methods 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 241000172147 Saprolegnia diclina Species 0.000 abstract 1
- 241000144181 Thraustochytrium aureum Species 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000002906 microbiologic effect Effects 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 239000003921 oil Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6431—Linoleic acids [18:2[n-6]]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6432—Eicosapentaenoic acids [EPA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6434—Docosahexenoic acids [DHA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
Abstract
Secuencia de nucleótidos aislada, o fragmento, que comprende o que es complementaria en por lo menos un 50% aproximadamente de la secuencia de nucleótidos que comprende la SEQ ID N° 13, la SEQ ID N° 19 o la SEQ ID N° 28, SEQ ID N° 30, SEQ ID N° 32 o SEQ ID N° 34. Estas secuencias pueden codificar una desaturasa funcionalmente activa (proteína purificada) que utiliza un ácido graso poliinsaturado como sustrato. Las secuencias pueden derivar, de Saprolegnia diclina (SEQ ID N° 13 y SEQ ID N° 19), Thraustochytrium aureum (SEQ ID N° 28, SEQ ID N° 30 y SEQ ID N° 32) o de Isochysis galbana (SEQ ID N° 34). Además se incluyen las proteínas purificadas codificadas por las secuencias de nucleótidos a las que se hizo referencia previamente. Aún más, también se revela un método para producir una desaturasa. También se describe un vector que comprende la secuencia de nucleótidos representada en la SEQ ID N° 13, SEQ ID N° 19, SEQ ID N° 28, SEQ ID N° 30, SEQ ID N° 32 o SEQ ID N° 34 ligada operativamente a una secuencia promotora o reguladora. Una célula huésped, una célula de mamífero, una célula vegetal, una planta, un tejido vegetal o una planta transgénica que comprendan este vector, también se detallan así como los ácidos o aceites que se expresan. Además, se incluye un método para producir un ácido graso poliinsaturado así como una composición nutricional que comprende por lo menos un ácido graso poliinsaturado seleccionado del grupo formado por el producto de ácido graso poliinsaturado producido de acuerdo con los métodos descriptos previamente. Las desaturasas son criticas para la producción de ácidos grasos poliinsaturados de cadena larga (PUFA) que cumplen muchas funciones importantes como por ejemplo en la membrana plasmática de una célula, donde se encuentran en la forma de fosfolípidos. Resulta de interés aislar los genes involucrados en la síntesis de PUFA provenientes de especies que producen éstos ácidos grasos de forma natural y expresar dichos genes en un sistema microbiológico, vegetal o animal que pueda ser alterado para proveer la producción de cantidades comerciales de uno o varios PUFA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/769,863 US6635451B2 (en) | 2001-01-25 | 2001-01-25 | Desaturase genes and uses thereof |
US10/054,534 US7067285B2 (en) | 2001-01-25 | 2002-01-22 | Desaturase genes and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035534A1 true AR035534A1 (es) | 2004-06-02 |
Family
ID=27735000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020100289A AR035534A1 (es) | 2001-01-25 | 2002-01-25 | Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion |
Country Status (8)
Country | Link |
---|---|
US (6) | US6635451B2 (es) |
EP (2) | EP2333052B1 (es) |
JP (3) | JP4347397B2 (es) |
AR (1) | AR035534A1 (es) |
AT (1) | ATE535602T1 (es) |
CA (2) | CA2698579C (es) |
ES (1) | ES2377198T3 (es) |
PT (1) | PT1392823E (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6635451B2 (en) * | 2001-01-25 | 2003-10-21 | Abbott Laboratories | Desaturase genes and uses thereof |
US20050089879A1 (en) * | 2001-07-31 | 2005-04-28 | Ivo Feussner | Method for producing arachidonic acid in transgenic organisms |
DE10219203A1 (de) * | 2002-04-29 | 2003-11-13 | Basf Plant Science Gmbh | Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in Pflanzen |
CA2518197A1 (en) * | 2003-03-07 | 2004-09-23 | Advanced Bionutrition Corporation | Feed formulation for terrestrial and aquatic animals |
ES2323644T3 (es) | 2003-08-21 | 2009-07-22 | Monsanto Technology Llc | Desaturasas de acidos grasos procedentes de primula. |
US8378186B2 (en) | 2004-04-16 | 2013-02-19 | Monsanto Technology Llc | Expression of fatty acid desaturases in corn |
US7807849B2 (en) | 2004-04-22 | 2010-10-05 | Commonwealth Scientific And Industrial Research Organisation | Synthesis of long-chain polyunsaturated fatty acids by recombinant cells |
CA3023314C (en) | 2004-04-22 | 2019-12-10 | Commonwealth Scientific And Industrial Research Organisation | Synthesis of long-chain polyunsaturated fatty acids by recombinant cells |
AU2011232757B2 (en) * | 2004-04-22 | 2013-10-03 | Commonwealth Scientific And Industrial Research Organisation | Synthesis of long-chain polyunsaturated fatty acids by recombinant cells |
US7364883B2 (en) * | 2004-05-07 | 2008-04-29 | Yeastern Biotech Co., Ltd. | Process for producing poly-unsaturated fatty acids by oleaginous yeasts |
WO2005118814A2 (en) * | 2004-06-04 | 2005-12-15 | Fluxome Sciences A/S | Metabolically engineered cells for the production of polyunsaturated fatty acids |
US7588931B2 (en) * | 2004-11-04 | 2009-09-15 | E. I. Du Pont De Nemours And Company | High arachidonic acid producing strains of Yarrowia lipolytica |
US8685679B2 (en) * | 2004-11-04 | 2014-04-01 | E I Du Pont De Nemours And Company | Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms |
BRPI0608637A2 (pt) | 2005-03-16 | 2010-01-19 | Metabolix Inc | vetor recombinante para expressço de enzimas, cÉlula de planta transformada, mÉtodo para produÇço de produto biossintÉtico |
JP5033122B2 (ja) | 2005-05-23 | 2012-09-26 | アルカディア バイオサイエンシズ,インコーポレイテッド | 増量ガンマ−リノレン酸を含むベニバナ |
EP3238543B1 (en) | 2005-06-07 | 2019-03-20 | DSM Nutritional Products AG | Eukaryotic microorganisms for producing lipids and antioxidants |
EP1991047B1 (en) | 2006-03-01 | 2012-09-26 | Pioneer Hi-Bred International Inc. | Compositions related to the quantitative trait locus 6 (qtl6) in maize and methods of use |
US7465793B2 (en) | 2006-04-20 | 2008-12-16 | E.I. Du Pont De Nemours And Company | Synthetic Δ17 desaturase derived from Phytophthora ramourum and its use in making polyunsaturated fatty acids |
CA2659603C (en) * | 2006-08-01 | 2017-03-07 | Ocean Nutrition Canada Limited | Oil producing microbes and methods of modification thereof |
EP2059588A4 (en) | 2006-08-29 | 2010-07-28 | Commw Scient Ind Res Org | FATTY ACID SYNTHESIS |
AU2007314481B2 (en) * | 2006-10-30 | 2012-11-29 | E. I. Du Pont De Nemours And Company | Delta17 desaturase and its use in making polyunsaturated fatty acids |
US7943365B2 (en) * | 2007-05-03 | 2011-05-17 | E.I. Du Pont De Nemours And Company | Δ-5 desaturases and their use in making polyunsaturated fatty acids |
JP2010533003A (ja) * | 2007-07-13 | 2010-10-21 | オーシャン ニュートリッション カナダ リミテッド | D4デサチュラーゼ及びd5エロンガーゼ |
EP2304032A1 (en) * | 2008-08-01 | 2011-04-06 | E. I. du Pont de Nemours and Company | 6 desaturases and their use in making polyunsaturated fatty acids |
DK2358882T3 (da) | 2008-11-18 | 2017-11-06 | Commw Scient Ind Res Org | Enzymer og fremgangsmåder til fremstilling af omega-3 fedtsyrer |
US8916154B2 (en) * | 2009-04-27 | 2014-12-23 | Abbott Laboratories | Antibodies against delta-5 desaturase and uses thereof |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
KR102197208B1 (ko) | 2012-06-15 | 2021-01-04 | 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 | 식물 세포에서 장쇄 다중불포화 지방산의 생성 |
ES2666895T3 (es) | 2013-03-13 | 2018-05-08 | Dsm Nutritional Products Ag | Modificación genética de microorganismos |
PE20170253A1 (es) | 2013-12-18 | 2017-04-14 | Nuseed Pty Ltd | Lipido que comprende acidos grasos poliinsaturados de cadena larga |
US10473585B2 (en) * | 2014-06-16 | 2019-11-12 | Murphy Brown, Llc | Method and system for measuring a physical parameter of a particulate material |
CA2953008C (en) | 2014-06-27 | 2024-03-19 | Nuseed Pty Ltd | Lipid comprising docosapentaenoic acid |
CN112741154A (zh) * | 2019-10-30 | 2021-05-04 | 东北农业大学 | 一种早产儿配方液态乳及其制备方法 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL63907A0 (en) | 1980-09-24 | 1981-12-31 | Cetus Corp | Diagnostic method and antibody probe for use therein |
US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5420034A (en) | 1986-07-31 | 1995-05-30 | Calgene, Inc. | Seed-specific transcriptional regulation |
US4943674A (en) | 1987-05-26 | 1990-07-24 | Calgene, Inc. | Fruit specific transcriptional factors |
GB8507058D0 (en) | 1985-03-19 | 1985-04-24 | Efamol Ltd | Pharmaceutical & dietary compositions |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8524275D0 (en) | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
GB8524276D0 (en) | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
US5107065A (en) | 1986-03-28 | 1992-04-21 | Calgene, Inc. | Anti-sense regulation of gene expression in plant cells |
US5188958A (en) | 1986-05-29 | 1993-02-23 | Calgene, Inc. | Transformation and foreign gene expression in brassica species |
CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
US5004863B2 (en) | 1986-12-03 | 2000-10-17 | Agracetus | Genetic engineering of cotton plants and lines |
US5416011A (en) | 1988-07-22 | 1995-05-16 | Monsanto Company | Method for soybean transformation and regeneration |
US5130242A (en) | 1988-09-07 | 1992-07-14 | Phycotech, Inc. | Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids |
US5116871A (en) | 1988-09-13 | 1992-05-26 | Efamol Holdings Plc | Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis |
US5231020A (en) | 1989-03-30 | 1993-07-27 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
US5106739A (en) | 1989-04-18 | 1992-04-21 | Calgene, Inc. | CaMv 355 enhanced mannopine synthase promoter and method for using same |
US5196198A (en) | 1989-06-02 | 1993-03-23 | Abbott Laboratories | Parenteral nutrition product |
US5175095A (en) | 1989-07-19 | 1992-12-29 | Calgene, Inc. | Ovary-tissue transcriptional factors |
CA2083259C (en) | 1990-05-25 | 2007-05-15 | William D. Hitz | Nucleotide sequence of soybean stearoyl-acp desaturase gene |
US5518908A (en) | 1991-09-23 | 1996-05-21 | Monsanto Company | Method of controlling insects |
PH31293A (en) | 1991-10-10 | 1998-07-06 | Rhone Poulenc Agrochimie | Production of y-linolenic acid by a delta6-desaturage. |
DK0616644T3 (da) | 1991-12-04 | 2003-10-27 | Du Pont | Fedtsyredesaturase-gener fra planter |
US5912120A (en) | 1992-04-09 | 1999-06-15 | The United States Of America As Represented By The Department Of Health And Human Services, | Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism |
DK0668919T3 (da) | 1992-11-17 | 2003-09-15 | Du Pont | Gener for mikorsomale delta-12-fedtsyredesaturaser og beslægtede enzymer fra planter |
ATE193729T1 (de) | 1993-02-26 | 2000-06-15 | Calgene Llc | Geminivirus-basiertes-genexpressionsystem |
JPH07228888A (ja) | 1994-02-17 | 1995-08-29 | Shimadzu Corp | 高度不飽和脂肪酸の精製方法 |
US5750176A (en) | 1994-03-09 | 1998-05-12 | Abbott Laboratories | Transgenic non-human mammal milk comprising 2'-fucosyl-lactose |
NZ281041A (en) | 1994-03-09 | 1998-04-27 | Abbott Lab | Non-human mammals transformed with a catalytic entity of enzymes or antibodies to produce a heterologous product in the animals milk |
JPH09509847A (ja) | 1994-03-09 | 1997-10-07 | アボツト・ラボラトリーズ | 人乳化乳 |
US5427857A (en) * | 1994-06-28 | 1995-06-27 | E. I. Du Pont De Nemours And Company | Cathodic electrocoating compositions containing branched epoxy amine resins |
US5631152A (en) | 1994-10-26 | 1997-05-20 | Monsanto Company | Rapid and efficient regeneration of transgenic plants |
US5654402A (en) | 1994-10-26 | 1997-08-05 | Michigan State University | Methods and compositions relating to plant Δ6 palmitoyl-acyl carrier protein desaturase |
JPH0913077A (ja) | 1995-07-04 | 1997-01-14 | Nisshin Oil Mills Ltd:The | 臓器蓄積性の高い油脂 |
CA2285939C (en) * | 1997-04-11 | 2010-06-15 | Calgene Llc | Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants |
US5972664A (en) * | 1997-04-11 | 1999-10-26 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids |
AU4544799A (en) | 1998-05-29 | 1999-12-13 | Ohio University | Compositions and methods for the synthesis of fatty acids, their derivatives and downstream products |
JP2000069987A (ja) | 1998-08-28 | 2000-03-07 | Suntory Ltd | アラキドン酸含有脂質並びにジホモ−γ−リノレン酸含有脂質の製造方法 |
WO2000020603A1 (en) | 1998-10-05 | 2000-04-13 | Abbott Laboratories | Altered fatty acid biosynthesis in insect cells using delta five desaturase |
EP1035207A1 (en) | 1999-03-09 | 2000-09-13 | MultiGene Biotech GmbH | cDNA molecules of the members of gene family encoding human fatty acid desaturases and their use in diagnosis and therapy |
PL357415A1 (en) | 1999-06-07 | 2004-07-26 | Basf Plant Science Gmbh | Delta6-acetylenase and delta6-desaturase from ceratodon purpureus |
DE60141760D1 (de) * | 2000-09-28 | 2010-05-20 | Bioriginal Food & Science Corp | Fad4, fad5, fad5-2, and fad6, mitglieder der fettsäuredesaturasefamilie und ihre verwendungen |
EP1392823B1 (en) | 2001-01-25 | 2011-11-30 | Abbott Laboratories | Desaturase genes and uses thereof |
US6635451B2 (en) | 2001-01-25 | 2003-10-21 | Abbott Laboratories | Desaturase genes and uses thereof |
-
2001
- 2001-01-25 US US09/769,863 patent/US6635451B2/en not_active Expired - Lifetime
-
2002
- 2002-01-22 US US10/054,534 patent/US7067285B2/en not_active Expired - Lifetime
- 2002-01-24 EP EP10185334.9A patent/EP2333052B1/en not_active Expired - Lifetime
- 2002-01-24 ES ES02736480T patent/ES2377198T3/es not_active Expired - Lifetime
- 2002-01-24 PT PT02736480T patent/PT1392823E/pt unknown
- 2002-01-24 CA CA2698579A patent/CA2698579C/en not_active Expired - Fee Related
- 2002-01-24 CA CA2699611A patent/CA2699611C/en not_active Expired - Fee Related
- 2002-01-24 EP EP10184220.1A patent/EP2325300B1/en not_active Expired - Lifetime
- 2002-01-24 AT AT02736480T patent/ATE535602T1/de active
- 2002-01-25 AR ARP020100289A patent/AR035534A1/es not_active Application Discontinuation
-
2003
- 2003-05-08 US US10/431,952 patent/US7241619B2/en not_active Expired - Fee Related
-
2007
- 2007-05-07 US US11/800,631 patent/US20090265798A1/en not_active Abandoned
-
2008
- 2008-05-13 JP JP2008125523A patent/JP4347397B2/ja not_active Expired - Fee Related
- 2008-06-11 JP JP2008152845A patent/JP4347400B2/ja not_active Expired - Fee Related
- 2008-06-11 JP JP2008152844A patent/JP4347399B2/ja not_active Expired - Fee Related
-
2010
- 2010-09-09 US US12/878,807 patent/US8143383B2/en not_active Expired - Fee Related
- 2010-09-09 US US12/878,788 patent/US8143486B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2008289490A (ja) | 2008-12-04 |
CA2699611A1 (en) | 2002-10-17 |
US8143486B2 (en) | 2012-03-27 |
ATE535602T1 (de) | 2011-12-15 |
EP2333052B1 (en) | 2013-10-09 |
US20110003360A1 (en) | 2011-01-06 |
JP4347400B2 (ja) | 2009-10-21 |
US20090265798A1 (en) | 2009-10-22 |
JP2008289479A (ja) | 2008-12-04 |
EP2325300A1 (en) | 2011-05-25 |
US7067285B2 (en) | 2006-06-27 |
US20030190733A1 (en) | 2003-10-09 |
JP4347397B2 (ja) | 2009-10-21 |
US20110003351A1 (en) | 2011-01-06 |
ES2377198T3 (es) | 2012-03-23 |
CA2699611C (en) | 2013-12-10 |
JP2008289491A (ja) | 2008-12-04 |
EP2333052A1 (en) | 2011-06-15 |
US20030167525A1 (en) | 2003-09-04 |
CA2698579C (en) | 2013-12-10 |
PT1392823E (pt) | 2012-03-08 |
US20030157144A1 (en) | 2003-08-21 |
US8143383B2 (en) | 2012-03-27 |
US7241619B2 (en) | 2007-07-10 |
EP2325300B1 (en) | 2013-11-06 |
JP4347399B2 (ja) | 2009-10-21 |
US6635451B2 (en) | 2003-10-21 |
CA2698579A1 (en) | 2002-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035534A1 (es) | Secuencia de nucleotidos aislada, polipeptido purificado, metodo para producir una desaturasa, vector, celula huesped, celula de mamiferos, celula vegetal, una planta y tejido vegetal, planta transgenica, acidos o aceites vegetales, metodo para producir un acido graso poliinsaturado y composicion | |
AU2018204726A1 (en) | Production of dihydrosterculic acid and derivatives thereof | |
US9222101B2 (en) | Method of producing fatty acids or lipids containing fatty acids using thioesterase variants | |
Faure et al. | Camelina, a Swiss knife for plant lipid biotechnology | |
RU2008149700A (ru) | Дельта-5-десатураза и ее применение для получения полиненасыщенных жирных кислот | |
CA2435685A1 (en) | Desaturase genes and uses thereof | |
JP2013509178A5 (es) | ||
JP6319889B2 (ja) | アシル−acpチオエステラーゼ改変体を用いた脂質の製造方法 | |
Yoshino et al. | Production of ω3 fatty acids in marine cyanobacterium Synechococcus sp. strain NKBG 15041c via genetic engineering | |
Wang et al. | Heterogeneous expression of human PNPLA3 triggers algal lipid accumulation and lipid droplet enlargement | |
Chi et al. | Fatty acid biosynthesis in eukaryotic photosynthetic microalgae: identification of a microsomal delta 12 desaturase in Chlamydomonas reinhardtii | |
JP2014527803A (ja) | トリアシルグリセロール(tag)リパーゼの遺伝子操作による微細藻類における脂質含量の増大 | |
Südfeld et al. | Expression of glycerol-3-phosphate acyltransferase increases non-polar lipid accumulation in Nannochloropsis oceanica | |
Huang et al. | Cloning and functional identification of delta5 fatty acid desaturase gene and its 5′-upstream region from marine fungus Thraustochytrium sp. FJN-10 | |
AU2015356285A1 (en) | Method of producing lipid using acyl-acp thioesterase | |
Chodok et al. | Metabolic engineering and oil supplementation of Physcomitrella patens for activation of C 22 polyunsaturated fatty acid production | |
RU2011114558A (ru) | Гены δ-8-десатуразы, ферменты, кодируемые ими, и их применение | |
CN104662154A (zh) | 使用硫酯酶变异体的脂质的制造方法 | |
Chenarani et al. | Characterization of sucrose binding protein as a seed-specific promoter in transgenic tobacco Nicotiana tabacum L. | |
Aziz et al. | Phosphate-induced changes in fatty acid biosynthesis in Chlorella sp. KS-MA2 strain | |
Thanasomboon et al. | Construction of synthetic Escherichia coli producing s-linalool | |
Sharma et al. | Genetic engineering in improving the output of algal biorefinery | |
US20240254500A1 (en) | Increasing the accumulation of epa and dha in recombinant camelina | |
CN109477060A (zh) | 增加tag产量的修饰藻类 | |
AU2017322897A1 (en) | Method of producing lipid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal | ||
FB | Suspension of granting procedure |